


Study  $I^2$


**Erlotinib\_chemotherapy vs Chemotherapy**

71  
Pooled (pair-wise)  
Indirect (back-calculated)  
Pooled (network) 0.0%




**Gefitinib vs Chemotherapy**

73  
75  
76  
77  
Pooled (pair-wise) 54.0%  
Indirect (back-calculated)  
Pooled (network) 27.6%




**Osimertinib vs Chemotherapy**


42  
Pooled (pair-wise)  
Indirect (back-calculated)  
Pooled (network) 0.0%





**Erlotinib vs Dacomitinib**


45  
59  
Pooled (pair-wise) 0.0%  
Indirect (back-calculated)  
Pooled (network) 0.0%



















Study  $I^2$

**Osimertinib\_antiangio vs Osimertinib**

5

6

8

Pooled (pair-wise) 48.3%

Indirect (back-calculated)

Pooled (network) 48.9%

**Placebo vs Osimertinib**

10

r19

Pooled (pair-wise) 0.0%

Indirect (back-calculated)

Pooled (network) 0.0%

